Markus Cappel

Markus Cappel, Ph.D., MBA, is the Chairman of the Board of Directors at OSE Immunotherapeutics, where they guide governance and set the company’s strategic direction. They are an accomplished biotechnology executive with expertise in strategy, product management, M&A/IPO, financings, contract negotiations, and organizational design. In their most recent role as Chief Business Officer at ChemoCentryx, they led efforts that contributed to Amgen’s $4 billion acquisition and helped raise $435 million in public offerings (including an IPO) and $138 million in private financing. They led product development and commercialization of TAVNEOS across seven major market countries and oversaw the global commercial supply, while pursuing a BS in Pharmacy and a PhD in Pharmaceutical Technology at Goethe University College of Pharmacy, and they earned MBAs from Harvard Business School.